摘要
目的:分析海曲泊帕乙醇胺片^(+)重组人血小板生成素(rhTPO)对实体瘤化疗后血小板减少症患者的治疗效果。方法:选取2022年1月—2023年1月句容市人民医院收治的88例实体瘤化疗后血小板减少症患者,按随机数字表法分为两组,各44例。对照组予以rhTPO治疗,观察组在对照组基础上加以海曲泊帕乙醇胺片治疗,均持续治疗2周。对比两组临床疗效、血小板参数、免疫功能、不良反应。结果:观察组治疗总有效率为95.45%(42/44),高于对照组的81.82%(36/44),差异有统计学意义(P<0.05);治疗前,两组血小板计数(PLT)、血小板压积(PCT)、平均血小板体积(MPV)、血小板体积分布宽度(PDW)、CD3^(+)、CD4^(+)、CD8^(+)对比,差异均无统计学意义(P>0.05);治疗后,观察组PLT为(136.97±10.63)×10^(9)/L、PCT^(+)^(+)为(0.20±0.07)%、CD3为(54.38±6.25)%、CD4为(48.39±5.40)%,均高于对照组的(100.83±8.39)×10^(9)/L、(0.15±0.05)%、(49.75±5.42)%、^(+)(41.64±4.39)%,MPV为(13.21±2.20)fL、PDW为(15.20±2.58)%、CD8为(24.26±1.58)%,均低于对照组的(17.46±2.58)fL、(19.52±3.21)%、(28.71±2.26)%,差异均有统计学意义(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论:海曲泊帕乙醇胺片^(+)rhTPO能够提高实体瘤化疗后血小板减少症患者PLT,改善免疫功能,且无严重不良反应。
Objective:To analyze the therapeutic effect of Herombopag Olamine Tablets^(+)Recombinant Human Thrombopoietin(rhTPO)on patients with thrombocytopenia after chemotherapy for solid tumor.Method:A total of 88 patients with thrombocytopenia after chemotherapy for solid tumor in Jurong People Hospital from January 2022 to January 2023 were selected and divided into two groups according to random number table method,with 44 cases in each group.The control group was treated with rhTPO,and the observation group was treated with Herombopag Olamine Tablets on the basis of the control group,and both of them continued to be treated for 2 weeks.The clinical efficacy,platelet parameters,immune function and adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was 95.45%(42/44),which was higher than 81.82%(36/44)in the control group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in platelet count(PLT),plateletcrit(PCT),mean platelet volume(MPV),platelet distribution width(PDW),CD3^(+),^(+)^(+)CD4 and CD8 between the two groups(P>0.05);after treatment,PLT was(136.97±10.63)×10^(9)/L,^(+)^(+)PCT was(0.20±0.07)%,CD3 was(54.38±6.25)%and CD4 was(48.39±5.40)%in the observation group,which were higher than(100.83±8.39)×10^(9)/L,(0.15±0.05)%,(49.75±5.42)%,(41.64±4.39)%in the^(+)control group,MPV was(13.21±2.20)fL,PDW was(15.20±2.58)%,CD8 was(24.26±1.58)%in the observation group,which were lower than(17.46±2.58)fL,(19.52±3.21)%,(28.71±2.26)%in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Herombopag Olamine Tablets^(+)rhTPO can increase PLT and improve immune function in patients with thrombocytopenia after chemotherapy for solid tumor,and without serious adverse reactions.
作者
王亚敏
WANG Yamin(Department of Hematology and Oncology,Jurong People Hospital,Jurong 212400,China)
出处
《中国医学创新》
CAS
2024年第14期65-68,共4页
Medical Innovation of China
关键词
实体瘤
化疗
血小板减少症
不良反应
Solid tumor
Chemotherapy
Thrombocytopenia
Adverse reactions
